Extensive-stage small cell lung cancer (SCLC) is a challenging diagnosis, as it indicates the cancer has spread beyond the chest to other parts of the body. Treatment for this stage typically involves a combination of chemotherapy and immunotherapy, aiming to control the disease and improve survival.
Recent data showed that the addition of immunotherapy (atezolizumab or durvalumab), targeting PD-L1, to the standard chemotherapy regimen of carboplatin and etoposide can significantly improve outcomes for patients with advanced small cell lung cancer.